Nevertheless, our analysis reports on the early period following the introduction of CDK4/6 inhibitors, and there is evidence of an increasing trend in utilization in the years following its introduction [ 35 ].
← all excerpts
Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer.
1
—
—